Australia's BCAL Diagnostics rises on licence agreement with US-based firm

BCAL Diagnostics

18/09/2025 02:20

** Shares of BCAL Diagnostics BDX.AX up as much as 7.7% at A$0.07, their highest level since July 18

** The biotechnology co entersexclusive licence agreement with U.S.-based ClearNote Health Inc for the distribution of ClearNote Health's pancreatic and ovarian cancer blood tests in Australia and New Zealand

** About 411,748 shares change hands, 2.3x 30-day average volume

** Stock currently up 6.2%, bringing YTD losses to 28.9%

 (Reporting by Sherin Sunny in Bengaluru)

 ((Sherin.Sunny@thomsonreuters.com))